8-K: Century Therapeutics Reports Strong 2025, Extends Runway

Century Therapeutics significantly reduced its net loss and extended its cash runway into 2029, driven by increased collaboration revenue and a successful $135 million private placement.

Summary

• Century Therapeutics reported full year 2025 financial results, showing a significant reduction in net loss and a substantial increase in collaboration revenue.
• The company completed an oversubscribed $135 million private placement in January 2026, extending its cash runway into the first quarter of 2029.
• CNTY-813, a lead beta islet cell therapy program for type 1 diabetes, is advancing through IND-enabling studies with an IND submission expected in 4Q 2026 and initial clinical data anticipated in 2H 2027.
• Preclinical data for CNTY-813 demonstrated high potency, long duration for functional glucose control, and protection against immune rejection via Allo-Evasion 5.0 engineering.
• CNTY-308, a CD19-targeted CAR-iT cell therapy with Allo-Evasion 5.0 for B-cell-mediated diseases, is on track to enter the clinic in 2026.
• Updated preliminary clinical data from the ongoing CARAMEL Phase 1/2 investigator-sponsored trial (IST) for CNTY-101 in autoimmune diseases is expected in 2026.
• Han Lee, Ph.D., M.B.A., and Martin Murphy, Ph.D., were appointed to the Board of Directors in December 2025.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive update, driven by significant financial improvements, a successful capital raise extending the cash runway, and promising preclinical data for its lead programs, particularly CNTY-813, which addresses a major unmet medical need.

Positives

• Net loss significantly reduced to $9.6 million for the year ended December 31, 2025, compared to $126.6 million for the same period in 2024.
• Collaboration revenue increased substantially to $109.2 million for 2025, up from $6.6 million in 2024.
• Successful completion of an oversubscribed $135 million private placement in January 2026.
• Cash runway extended into the first quarter of 2029, providing financial stability for pipeline advancement.
• R&D expenses decreased to $95.7 million in 2025 from $107.2 million in 2024, primarily due to reduced personnel and manufacturing costs.
• G&A expenses decreased to $24.0 million in 2025 from $33.2 million in 2024, driven by lower legal fees, a gain on lease modification, and a reduction in contingent consideration liability.
• CNTY-813, the priority program for type 1 diabetes, is progressing with compelling preclinical data, demonstrating functional glucose control for over 6 months in animal models and protection against immune rejection.
• Constructive interactions with the FDA reinforce confidence in an efficient pathway to IND submission for CNTY-813.
• CNTY-308 is advancing towards clinical entry in 2026, with preclinical studies showing functional comparability to primary CAR-T cells.
• Early signs of clinical response observed for CNTY-101 in autoimmune diseases from the CARAMEL IST, with the therapy generally well tolerated.
• Appointment of two experienced new members, Han Lee, Ph.D., M.B.A., and Martin Murphy, Ph.D., to the Board of Directors.

Negatives

• Cash, cash equivalents, and marketable securities decreased to $117.1 million as of December 31, 2025, from $220.1 million as of December 31, 2024, prior to the January 2026 capital raise.
• The company continues to operate at a net loss, despite significant improvements.
• Weighted average common shares outstanding increased to 86,556,515 in 2025 from 78,648,958 in 2024, indicating dilution from capital raising activities.

Risks

• Ability to successfully advance current and future product candidates through development activities, preclinical studies, and clinical trials.
• Ability to meet development milestones on anticipated timelines.
• Uncertainties inherent in the results of preliminary data, preclinical studies, and earlier-stage clinical trials, which may not be predictive of final results or the results of later-stage clinical trials.
• Ability to obtain clearance of future IND or CTA submissions and commence and complete clinical trials on expected timelines, or at all.
• Reliance on the maintenance of certain key collaborative relationships for the manufacturing and development of product candidates.
• The timing, scope, and likelihood of regulatory filings and approvals, including final regulatory approval of product candidates.
• The impact of geopolitical issues, trade disputes and tariffs, banking instability, and inflation on business and operations, supply chain, and labor force.
• The performance of third parties in connection with the development of product candidates, including third parties conducting clinical trials as well as third-party suppliers and manufacturers.
• Ability to successfully commercialize product candidates and develop sales and marketing capabilities, if product candidates are approved.
• Ability to recruit and maintain key members of management and ability to maintain and successfully enforce adequate intellectual property protection.

Future Outlook

Century Therapeutics expects to submit an Investigational New Drug (IND) application for CNTY-813 in the fourth quarter of 2026, with initial clinical data anticipated in the second half of 2027. CNTY-308 is projected to enter the clinic in 2026, and updated preliminary clinical data from the CARAMEL IST for CNTY-101 is also expected in 2026. The company's cash, cash equivalents, and investments, including net proceeds from the recent private placement, are estimated to support operations into the first quarter of 2029.

Management Comments

• "Century entered 2026 with strong momentum, fueled by the successful completion of our $135 million private placement and continued focus on advancing our prioritized programs closer to patients living with significant unmet medical need."
• "We are moving fast and executing with precision on CNTY-813, our top priority and a program we believe has the potential to functionally cure type 1 diabetes."
• "Recent achievements, including compelling preclinical results combined with constructive interactions with the FDA, strengthen our confidence in the clinical path ahead."
• "We are energized by the progress across our pipeline, confident in the road ahead, and focused on advancing our most promising programs into the clinic."

Industry Context

StockSavvy.ai notes that Century Therapeutics is operating in the highly competitive and innovative field of iPSC-derived cell therapies, particularly for autoimmune diseases and cancer. The focus on Type 1 Diabetes with CNTY-813 positions them in a high-unmet-need area where existing beta islet cell replacement therapies face limitations in cell source and chronic immunosuppression. Their Allo-Evasion 5.0 technology aims to overcome these challenges, potentially offering a significant advantage over current approaches like cadaveric islet transplantation or even other stem-cell derived islets (e.g., Vertex's VX-880, which still requires immunosuppression). The advancement of CAR-iT and CAR-iNK therapies aligns with the broader industry trend of developing allogeneic, off-the-shelf cell therapies to improve accessibility and reduce manufacturing complexity compared to autologous CAR-T cells.

Comparison to Industry Standards

• CNTY-813 (iPSC Beta Islets with Allo-Evasion 5.0) aims to provide glucose control, a scalable drug product, and be free of immune suppression, based on preclinical data. This compares favorably to:
• Cadaveric Islets: Provide glucose control but lack a scalable drug product and require chronic immune suppression.
• Stem-cell Beta Islets (e.g., Zimislecel/VX-880): Provide glucose control and a scalable drug product but still require chronic immune suppression.
• CNTY-308 (iPSC-derived CAR-T cells) demonstrated functional comparability to primary CAR-T cells in preclinical studies, including target-mediated IL-2 secretion, high functional persistence (killing for >10 rounds, persisting in blood for 32+ days), and tumor control after rechallenge. This suggests it could offer 'autologous, CAR-T-like clinical benefits in an allogeneic, patient-centric format' for enhanced treatment accessibility.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Positive impact due to extended cash runway, significantly reduced net loss, increased collaboration revenue, and promising pipeline progress, potentially leading to increased share value. Dilution from the recent capital raise is a consideration.
• Patients: Potential for new, more accessible, and effective therapies for type 1 diabetes and B-cell-mediated autoimmune diseases, especially with the Allo-Evasion technology aiming to reduce or eliminate chronic immunosuppression.
• Employees: Continued stability and focus on advancing key programs, potentially fostering a positive work environment and job security.
• Creditors: Improved financial health and extended cash runway reduce immediate solvency concerns, enhancing creditworthiness.
• Partners (e.g., Bristol-Myers Squibb): Strong collaboration revenue indicates successful partnership and potential for continued joint development.

Next Steps

• Submit IND for CNTY-813 in 4Q 2026.
• Anticipate initial clinical data for CNTY-813 in 2H 2027.
• CNTY-308 expected to enter the clinic in 2026.
• Updated preliminary clinical data from the CARAMEL IST (CNTY-101) expected in 2026.
• Continue patient enrollment for CNTY-101 in Phase 1/2 CARAMEL IST.

Key Dates

Recommendation

The company has demonstrated significant financial improvement, drastically reducing its net loss and substantially increasing collaboration revenue. The successful $135 million private placement extends the cash runway into 2029, providing ample capital to advance its promising pipeline. Key programs like CNTY-813 for Type 1 Diabetes, with compelling preclinical data and a clear path to IND submission and clinical data, represent a potential functional cure in a large market with high unmet need. The Allo-Evasion technology offers a differentiated approach to overcome major limitations of existing cell therapies. These factors collectively indicate strong operational execution and future growth potential, making it an attractive investment.

Keywords

Century Therapeutics, iPSC, Cell Therapy, Type 1 Diabetes, Autoimmune Disease, Cancer, Allo-Evasion, CNTY-813, CNTY-308, CAR-T, CAR-iT, CAR-iNK, Biotechnology, Financial Results, Clinical Trials, IND Submission, Private Placement, Cash Runway